SMARCB1 and neoplasm: Whilst this is a small proportion (n = 3) of total ATRT-SHH tumours (n = 65), SMARCA4 mutation does occur at a much lower rate compared to SMARCB1 in ATRT and its exclusivity to the SHH subgroup is notable.